ILEVRO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7947295 | NOVARTIS | Ophthalmic compositions containing a synergistic combination of two polymers |
Jun, 2024
(8 months from now) | |
| US9662398 | NOVARTIS | Carboxylvinyl polymer-containing nanoparticle suspensions |
Dec, 2030
(7 years from now) | |
| US8921337 | NOVARTIS | Carboxyvinyl polymer-containing nanoparticle suspensions |
Mar, 2032
(8 years from now) | |
Ilevro is owned by Novartis.
Ilevro contains Nepafenac.
Ilevro has a total of 3 drug patents out of which 0 drug patents have expired.
Ilevro was authorised for market use on 16 October, 2012.
Ilevro is available in suspension/drops;ophthalmic dosage forms.
The generics of Ilevro are possible to be released after 31 March, 2032.
Drugs and Companies using NEPAFENAC ingredient
Market Authorisation Date: 16 October, 2012
Treatment: NA
Dosage: SUSPENSION/DROPS;OPHTHALMIC
How can I launch a generic of ILEVRO before it's drug patent expiration?
More Information on Dosage
ILEVRO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic